477 related articles for article (PubMed ID: 32959085)
1. Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT).
Helmberger T; Golfieri R; Pech M; Pfammatter T; Arnold D; Cianni R; Maleux G; Munneke G; Pellerin O; Peynircioglu B; Sangro B; Schaefer N; de Jong N; Bilbao JI; ;
Cardiovasc Intervent Radiol; 2021 Jan; 44(1):21-35. PubMed ID: 32959085
[TBL] [Abstract][Full Text] [Related]
2. Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in France.
Loffroy R; Ronot M; Greget M; Bouvier A; Mastier C; Sengel C; Tselikas L; Arnold D; Maleux G; Pelage JP; Pellerin O; Peynircioglu B; Sangro B; Schaefer N; Urdániz M; Kaufmann N; Bilbao JI; Helmberger T; Vilgrain V;
Cardiovasc Intervent Radiol; 2021 Jan; 44(1):36-49. PubMed ID: 32975600
[TBL] [Abstract][Full Text] [Related]
3. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study.
Kolligs F; Arnold D; Golfieri R; Pech M; Peynircioglu B; Pfammatter T; Ronot M; Sangro B; Schaefer N; Maleux G; Munneke G; Pereira H; Zeka B; de Jong N; Helmberger T;
JHEP Rep; 2023 Feb; 5(2):100633. PubMed ID: 36593888
[TBL] [Abstract][Full Text] [Related]
4. Predictive Factors for Adverse Event Outcomes After Transarterial Radioembolization with Yttrium-90 Resin Microspheres in Europe: Results from the Prospective Observational CIRT Study.
Maleux G; Albrecht T; Arnold D; Bargellini I; Cianni R; Helmberger T; Kolligs F; Munneke G; Peynircioglu B; Sangro B; Schaefer N; Pereira H; Zeka B; de Jong N; Bilbao JI;
Cardiovasc Intervent Radiol; 2023 Jul; 46(7):852-867. PubMed ID: 36914788
[TBL] [Abstract][Full Text] [Related]
5. Factors Impacting Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Combined Analysis of the Prospective CIRT Studies.
Reimer P; Vilgrain V; Arnold D; Balli T; Golfieri R; Loffroy R; Mosconi C; Ronot M; Sengel C; Schaefer N; Maleux G; Munneke G; Peynircioglu B; Sangro B; Kaufmann N; Urdaniz M; Pereira H; de Jong N; Helmberger T
Cardiovasc Intervent Radiol; 2024 Mar; 47(3):310-324. PubMed ID: 38321223
[TBL] [Abstract][Full Text] [Related]
6. Survival and Toxicities after
Emmons EC; Bishay S; Du L; Krebs H; Gandhi RT; Collins ZS; O'Hara R; Akhter NM; Wang EA; Grilli C; Brower JS; Peck SR; Petroziello M; Abdel Aal AK; Golzarian J; Kennedy AS; Matsuoka L; Sze DY; Brown DB
Radiology; 2022 Oct; 305(1):228-236. PubMed ID: 35762890
[TBL] [Abstract][Full Text] [Related]
7. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry.
Wong TY; Zhang KS; Gandhi RT; Collins ZS; O'Hara R; Wang EA; Vaheesan K; Matsuoka L; Sze DY; Kennedy AS; Brown DB
BMC Cancer; 2022 Mar; 22(1):224. PubMed ID: 35232410
[TBL] [Abstract][Full Text] [Related]
9. Resin Versus Glass Microspheres for
Van Der Gucht A; Jreige M; Denys A; Blanc-Durand P; Boubaker A; Pomoni A; Mitsakis P; Silva-Monteiro M; Gnesin S; Lalonde MN; Duran R; Prior JO; Schaefer N
J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436
[TBL] [Abstract][Full Text] [Related]
10. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
[TBL] [Abstract][Full Text] [Related]
11. Clinical Application of Radioembolization in Hepatic Malignancies: Protocol for a Prospective Multicenter Observational Study.
Helmberger T; Arnold D; Bilbao JI; de Jong N; Maleux G; Nordlund A; Peynircioglu B; Sangro B; Sharma RA; Walk A
JMIR Res Protoc; 2020 Apr; 9(4):e16296. PubMed ID: 32319960
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Factors for Effectiveness Outcomes After Transarterial Radioembolization in Metastatic Colorectal Cancer: Results From the Multicentre Observational Study CIRT.
Schaefer N; Grözinger G; Pech M; Pfammatter T; Soydal C; Arnold D; Kolligs F; Maleux G; Munneke G; Peynircioglu B; Sangro B; Pereira H; Zeka B; de Jong N; Helmberger T;
Clin Colorectal Cancer; 2022 Dec; 21(4):285-296. PubMed ID: 36270925
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of results after 112 radioembolizations with
Casáns-Tormo I; Guijarro-Rosaleny J; Lluch-García P; Rodríguez-Parra H; Roselló-Keränen S; Asensio-Valero L
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(4):255-264. PubMed ID: 37269983
[TBL] [Abstract][Full Text] [Related]
14. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
Wang EA; Stein JP; Bellavia RJ; Broadwell SR
Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
[TBL] [Abstract][Full Text] [Related]
15. Combined Effects of Yttrium-90 Transarterial Radioembolization around Immunotherapy for Hepatic Metastases from Uveal Melanoma: A Preliminary Retrospective Case Series.
Zheng J; Irani Z; Lawrence D; Flaherty K; Arellano RS
J Vasc Interv Radiol; 2018 Oct; 29(10):1369-1375. PubMed ID: 30174161
[TBL] [Abstract][Full Text] [Related]
16. Real-world evidence of Pressure-Enabled Drug Delivery for trans-arterial chemoembolization and radioembolization among patients with hepatocellular carcinoma and liver metastases.
Cook K; Gupta D; Liu Y; Miller-Rosales C; Wei F; Tuttle E; Katz SC; Marshak R; Kim AY
Curr Med Res Opin; 2024 Apr; 40(4):591-598. PubMed ID: 38414420
[TBL] [Abstract][Full Text] [Related]
17. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Toxicity after Transarterial Radioembolization with Yttrium-90 Using Resin Microspheres for Neuroendocrine Tumor Liver Metastases.
Tomozawa Y; Jahangiri Y; Pathak P; Kolbeck KJ; Schenning RC; Kaufman JA; Farsad K
J Vasc Interv Radiol; 2018 Jun; 29(6):858-865. PubMed ID: 29724520
[TBL] [Abstract][Full Text] [Related]
19. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma.
Kallini JR; Gabr A; Salem R; Lewandowski RJ
Adv Ther; 2016 May; 33(5):699-714. PubMed ID: 27039186
[TBL] [Abstract][Full Text] [Related]
20. Incorporating Yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcioma: a single center experience.
Kim AY; Unger K; Wang H; Pishvaian MJ
BMC Cancer; 2016 Jul; 16():492. PubMed ID: 27430276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
